Safety and tolerability of 3-week and 6-month dosing of Deramaxx®(Deracoxib) chewable tablets in dogs
Authors:
- 1 August 2009
- journal article
- research article
- Published by Wiley in Journal of Veterinary Pharmacology and Therapeutics
- Vol. 32 (4) , 329-337
Abstract
Although non-steroidal anti-inflammatory drugs (NSAIDs) are effective in reducing pain and inflammation, these agents have adverse effects. Selective inhibitors of COX-2 are an alternative to traditional NSAIDs. Deramaxx [Novartis Animal Health US, Inc. (NAH), Greensboro, NC, USA] contains the selective COX-2 inhibitor, deracoxib, and is approved for the relief of pain and inflammation associated with orthopedic surgery and osteoarthritis in dogs. The safety of Deramaxx was evaluated in two target animal safety studies: 40 dogs (four dogs/sex/group) received 0, 4, 6, 8, or 10 mg/kg/day deracoxib once daily for 21 days; and 60 dogs (five dogs/sex/group) received 0, 2, 4, 6, 8, or 10 mg/kg/day deracoxib once daily for 6 months. There was a dose-dependent trend towards increased blood urea nitrogen (BUN) in treated dogs, however mean BUN values remained within the reference range at the labeled doses. In both trials, histopathology revealed focal renal tubular degeneration/regeneration in some dogs receiving >or=6 mg/kg/day deracoxib. Focal renal papillary necrosis was seen in one dog treated with 8 mg/kg/day and in three dogs receiving 10 mg/kg/day deracoxib on the 6-month study. No other parameters of renal function were adversely affected for either study. Results show that Deramaxx is safe and well-tolerated in dogs when administered as directed.Keywords
This publication has 20 references indexed in Scilit:
- Nonsteroidal anti-inflammatory drugs in cats: a reviewVeterinary Anaesthesia and Analgesia, 2007
- The Coxib NSAIDs: Potential Clinical and Pharmacologic Importance in Veterinary MedicineJournal of Veterinary Internal Medicine, 2005
- Renal Effects of Non-Steroidal Anti-Inflammatory Drugs and Selective Cyclooxygenase-2 InhibitorsCurrent Pharmaceutical Design, 2005
- Nonsteroidal Antiinflammatory Drugs: A ReviewJournal of the American Animal Hospital Association, 2005
- Pain and osteoarthritis: new drugs and mechanismsCurrent Opinion in Rheumatology, 2004
- Adverse drug event reports at the United States Food and Drug Administration Center for Veterinary MedicineJournal of the American Veterinary Medical Association, 2004
- Challenges and opportunities in animal drug development: a regulatory perspectiveNature Reviews Drug Discovery, 2003
- Selective COX-2 Inhibitors and Dual Acting Anti-inflammatory Drugs: Critical RemarksCurrent Medicinal Chemistry, 2002
- Dual acting anti-inflammatory drugs: a reappraisalPharmacological Research, 2001
- Physiologic characteristics and clinical importance of the cyclooxygenase isoforms in dogs and catsJournal of the American Veterinary Medical Association, 2000